Role of FDG-PET/CT in Assessment of Response to Therapy in Breast Cancer Patients | ||||
| Egyptian Journal Nuclear Medicine | ||||
| Article 2, Volume 8, Issue 8, December 2013, Page 7-14 PDF (505.97 K) | ||||
| Document Type: Original Paper, Oncology | ||||
| DOI: 10.21608/egyjnm.2013.5456 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Jehan Youniss 
| ||||
| Department Of Oncology & Nuclear Medicine,(NEMROCK), Faculty of Medicine, Cairo University, Cairo | ||||
| Abstract | ||||
| Objective: We aimed to assess the role of FDG PET/CT in evaluation of early response to chemotherapy after 2-3 cycles and late response after 6 cycles of chemotherapy to define responders from non-responders to treatment in breast cancer patients. Patients and Methods This prospective study included 52 female patients with locally advanced breast cancer, Group 1: Included 27 patients referred for PET/CT for assessment of primary lesion following 2-3 cycles of chemotherapy, twenty patients underwent a baseline study before initiation of therapy. Group 2: Included 25 patients with recurrent breast cancer referred for PET/CT following 6 cycles of chemotherapy for assessment of disease remission. They underwent a midline study after 2-3 cycles of chemotherapy. Results Only 4 patients out of 27 of group 1 showed significant early metabolic response with decrease of SUV value by (65.8%) following 2-3 cycles of treatment with significant reduction of mean SUV max implicating good response to therapy (p<0.005), while 23 patients showed partial metabolic response, with reduction of mean SUV max (36.2%). Nineteen out of 25 patients of group 2 (76%) showed significant metabolic response on completion of 6 cycles of chemotherapy with significant reduction of mean SUV max (69.6%) impressive of good therapy response (p<0.0001), while the other 6 patients (24%) showed poor metabolic response with mean reduction of SUV max of 30.8% and evidences of metastatic disease signifying poor therapy response. Conclusion: PET-CT seems to be useful for monitoring response to chemotherapy in locally advanced breast cancer differentiating responder from nonresponder in therapy evaluation. | ||||
| Keywords | ||||
| breast cancer; - 18 F -FDG-PET/CT; treatment monitoring | ||||
|
Statistics Article View: 187 PDF Download: 281 |
||||
